Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis.

It is possible to accurately identify newly diagnosed NAFL patients at high risk of progression to NASH or fibrosis. Early identification of these patients may allow for increased clinical monitoring, more aggressive preventative measures to slow the progression of NAFL and fibrosis, and efficient clinical trial enrollment.